´ëÇѺñ´¢±â°úÇÐȸ 2020 Á¦ 17Â÷ ÀÎõ.°æ±âÁöȸ Çмú´ëȸ : 2020-12-05±³À°ÀÏÀÚ : 2020-12-05
±³À°Àå¼Ò : ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£)
±³À°ÁÖÁ¦ :
2020 Á¦ 17Â÷ ÀÎõ.°æ±âÁöȸ Çмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ÀÎõ°æ±âÁöȸ
´ã´çÀÚ : ·ùÇö¿µ ¿¬¶ôó 02-573-8190
À̸ÞÀÏ :
urology@urology.or.kr ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
°æ±âµµ±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 12:00~12:30 µî·Ï ()
±âŸ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 12:30~12:40 Àλ縻 ()
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 12:40~12:50 1) Implication of microbiome for the management of LUTS À̱¤¿ì(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 12:50~13:00 2) TUC or hydro-dilatation for the management of interstitial cystitis ¿Àö¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 13:00~13:10 3) Management of post-operative complications of HoLEP ±è±¤ÅÃ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 13:10~13:20 4) How to manage a man with LUTS and underactive bladder Á¶°ÁØ(°¡Å縯ÀÇ´ë)
Åä·Ð 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 13:20~13:40 Panel Discussion ()
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 13:40~13:50 1) Focal therapy for prostate cancer: Mid-term outcomes and impact on salvage RP ÀÌÇйÎ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 13:50~14:00 2) Single vs dual androgen blockers of ADT in advanced prostate cancer ¹ÚÀ翵(°í·ÁÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 14:00~14:10 3) The timing and the adequate indication of cytoreductive nephrectomy in mRCC Ãß¼³È£(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 14:10~14:20 4) Preventive measure of intravesical recurrence in NMIBC: BCG or immune check point inhibitor ±è¼ºÇÑ(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 14:20~14:40 Panel Discussion ()
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 14:40~15:00 ȯÀÚÀÇ ÀÔÀå¿¡¼ »ý°¢ÇØ º¸ÀÚ! À̵¿È¯(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 15:00~15:20 ´Üü»çÁø ¹× Coffee break ()
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 15:20~15:40 COVID-19: Trend and Vaccine Á¤Á¾Å¹(¼¿ïÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 15:40~15:50 1) Update of Peyronie disease: shortening and lengthening À̼®¿µ(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 15:50~16:00 2) Concerns of TRT in the various conditions ÀÌÁ¤¿ì(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 16:00~16:10 3) Male HPV infection: treatment and vaccination ¹è»ó¶ô(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 16:10~16:20 4) Application and risk of low intensity SWL in male GU tract À±º´ÀÏ(°¡Å縯°üµ¿ÀÇ´ë)
Åä·Ð 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 16:20~16:40 Panel Discussion ()
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 16:40~16:50 1) Complications of retrograde intra-renal surgery: prevention and management Á¤Áø¿ì(°¡Å縯°üµ¿ÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 16:50~17:00 2) Preparation and surgical tips of ECIRS (Endoscopic Combined IntraRenal Surgery) ±èÁ¤±Ç(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 17:00~17:10 3) Graft surgery for the management of urethral stricture Á¤°æÁø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 17:10~17:20 4) Ureteral substitution with intestinal segments ±è¿õºó(¼øõÇâÀÇ´ë)
Åä·Ð 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 17:20~17:40 Panel Discussion ()
±âŸ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 17:40~18:00 ´ëÇѺñ´¢ÀÇÇÐȸ ÀÎõ¡¤°æ±âÁöȸ ÃÑȸ ()
±âŸ 12¿ù 05ÀÏ ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ȸÀÇ½Ç (406~408È£) 18:00~01:00 Closing ()